License and Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2020

Summary of Revenues by Collaboration and by Category of Revenue

The following table summarizes details of revenues for the three and nine months ended September 30, 2020 and 2019 by collaboration and by category of revenue:

			Three Months Ended September 30,				Nine Months Ended September 30,
Revenues recognized:	Over time	Point in time	2020		2019		2020		2019
Gilead license to zimberelimab		*	$	55,096	$	-	$	55,096	$	-
Gilead access rights related to the Company's research and development pipeline	*			7,684		-		7,684		-
Taiho collaboration agreement	*			1,750		1,750		5,250		5,250
Total collaboration and license revenue			$	64,530	$	1,750	$	68,030	$	5,250

Summary of Revenue Recognized as a Result of Changes in Deferred Revenue

The Company recognized the following revenue as a result of changes in the deferred revenue balance during the period below (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
Revenue recognized in the period from:	2020		2019		2020		2019
Amounts included in deferred revenue at the beginning of the period	$	1,750	$	1,750	$	5,250	$	5,250
Performance obligations satisfied in previous period		-		-		-		-

Schedule of Payments Allocated to Performance Obligations

These payments were allocated to the performance obligations identified as follows:

	September 30, 2020
Allocation of transaction price
Upfront cash consideration	$	175,000
Payment for access rights related to the Company's research and development pipeline		99,126
Premium from Stock Purchase Agreement		90,600
Total transaction price allocated to revenue	$	364,726
Allocation to performance obligations
Zimberelimab license	$	55,096
Etrumadenant option		126,657
Domvanalimab option		36,640
Access rights related to the Company's research and development pipeline		136,653
Development and commercialization services for zimberelimab		9,680
Total	$	364,726

Gilead and Taiho

Summary of Revenues

The following table summarizes the revenues for the three and nine months ended September 30, 2020 and 2019 received as a result of the Company’s collaboration agreements with Gilead Sciences, Inc. (Gilead) and Taiho Pharmaceutical Co., Ltd. (Taiho):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
License revenue	$	55,096	$	-	$	55,096	$	-
Collaboration revenue		9,434		1,750		12,934		5,250
Collaboration and license revenue	$	64,530	$	1,750	$	68,030	$	5,250